Pharmaceutical compositions comprising human hyaluronidase PH20 and a drug
A pharmaceutical composition with hyaluronidase PH20 and poloxamer-based surfactant enhances subcutaneous drug delivery by stabilizing enzyme activity and increasing absorption, addressing the limitations of conventional subcutaneous and intravenous injections.
Patent Information
- Application Number
- JP2024525296
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-29
- Filing Date
- 2022-10-28
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing subcutaneous injections of high-dose drugs face challenges with lower absorption rates and potential swelling at the injection site due to the neutral pH of the skin, limiting the volume to 2 mL or less, while intravenous injections are inconvenient and time-consuming.
A pharmaceutical composition containing hyaluronidase PH20 or its variants and a poloxamer-based surfactant is developed to enhance drug absorption through the skin by hydrolyzing hyaluronic acid, allowing for larger volumes and maintaining enzymatic activity and stability under neutral skin pH.
The composition enables stable and long-lasting drug delivery through subcutaneous injections, improving absorption rates and reducing swelling, thus facilitating convenient and effective administration of high-dose drugs.
Smart Images

Figure 2024541973000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition containing hyaluronidase PH20 or a variant thereof and one or more drugs, and a method for treating a disease using the same, wherein the composition contains a poloxamer-based surfactant.
[0002] The pharmaceutical composition according to the present invention can be used for the treatment of various diseases, and may be preferably used for subcutaneous injection. [Background technology]
[0003] Drugs that require high or large doses, especially antibody drugs, are generally administered by intravenous injection, but the injection time is more than 90 minutes, and the preparation work for intravenous injection is also required, which is very inconvenient for both patients and medical staff, and has the problem of additional costs. In contrast, subcutaneous injection has the advantage of being able to be administered immediately, but the absorption rate is lower than that of intravenous injection, and the absorption speed is slow, so that an injection volume of 3 to 5 mL or more may induce swelling and pain at the injection site. For this reason, subcutaneous injection of protein therapeutics is generally limited to small solution injections of 2 mL or less. However, if hyaluronidase is administered subcutaneously together with a therapeutic drug, the action of hyaluronidase hydrolyzes hyaluronic acid distributed in the extracellular matrix, reducing the viscosity of the subcutaneous layer and increasing substance permeability, and therefore high doses and large amounts of drugs can be easily delivered to the body.
[0004] There are six hyaluronidase genes in humans: Hyal1, Hyal2, Hyal3, Hyal4, HyalPS1, and PH20 / SPAM1. Hyal1 and Hyal2 are expressed in most tissues, and PH20 / SPAM1 (hereinafter referred to as PH20) is expressed in the cell membrane and acrosome membrane of sperm. HyalPS1 is a pseudogene and is not expressed. PH20 is an enzyme (EC3.2.1.35) that cleaves the β-1,4 bond between N-acetylglucosamine and glucuronic acid, which are the sugars that constitute hyaluronic acid. Human hyaluronidase PH20 has an optimum pH of 5.5 and shows some activity at pH 7-8, while other human hyaluronidases, including Hyal1, have an optimum pH of 3-4 and are very weakly active at pH 7-8. Since the pH of the subcutaneous area of humans is neutral at approximately pH 7.4, PH20 is widely used in clinical practice among various types of hyaluronidase. Examples of clinical uses of PH20 include subcutaneous injection of antibody therapeutic agents, eye relaxation agent and anesthesia injection additive during ophthalmic surgery, hydrolysis of hyaluronic acid in the extracellular matrix of tumor cells to increase the accessibility of anticancer therapeutic agents to tumor cells, and promotion of reabsorption of excess body fluids and blood in tissues.
[0005] On the other hand, the currently widely used commercial forms of PH20 are extracted from cow or sheep testicles, such as Amphadase (bovine hyaluronidase) and Vitrase (ovine hyaluronidase).
[0006] Recombinant human PH20 protein has been reported to be expressed in yeast (P. pastoris), DS-2 insect cells, animal cells, etc. (Chen et al., 2016, Hofinger et al., 2007). The recombinant PH20 protein produced in insect cells and yeast has a different N-glycosylation pattern from human PH20 during the post-translational modification process.
[0007] Research is being conducted to develop various therapeutic drugs in the form of subcutaneous injection dosage forms using human PH20, but the problem of the low stability of human PH20 itself remains unresolved.
[0008] Against this technical background, the inventors of the present invention have confirmed that a human PH20 mutant, which contains one or more amino acid substitutions in the alpha helix 8 site (S347-C381) and the junction site between alpha helix 7 and alpha helix 8 (A333-R346) in the amino acid sequence of wild-type hyaluronidase PH20, and in which some of the amino acids located at the N-terminus and / or C-terminus of PH20 are truncated, has very excellent enzymatic activity and thermal stability, and have filed a patent application (PCT / KR2019 / 009215).
[0009] Furthermore, the inventors of the present application have confirmed that PH20 or a variant thereof may be applied to a pharmaceutical composition or formulation containing a drug, preferably an antibody drug, specifically a high-dose anti-HER2 antibody or immune checkpoint antibody, and that, in particular, when the composition or formulation contains a poloxamer-based surfactant, the activity of the drug, such as an antibody drug, and PH20 or a variant thereof can be maintained very stably for a long period of time, thereby completing the present invention. Summary of the Invention
[0010] The present invention aims to provide a new pharmaceutical composition, which is characterized by containing a drug together with PH20 or a variant thereof and a poloxamer-based surfactant, and which can maintain the thermal stability and activity of the drug and PH20 or a variant thereof for a long period of time, particularly a pharmaceutical composition that can be used for subcutaneous administration.
[0011] Another object of the present invention is to provide a method for treating a disease, which comprises administering the pharmaceutical composition according to the present invention to a subject in need of such treatment.
[0012] In order to solve the above problems, the present invention provides The present invention provides a pharmaceutical composition comprising (a) a drug, (b) hyaluronidase, and (c) a poloxamer-based surfactant, wherein the hyaluronidase comprises wild-type PH20 having the sequence of SEQ ID NO:1 or a mutant thereof.
[0013] In the present invention, the hyaluronidase is preferably hyaluronidase PH20, particularly human PH20 or a mutant thereof, but is not limited thereto. The PH20 mutant has the amino acid sequence of SEQ ID NO: 1 and is selected from the group consisting of wild-type human PH20, T341S, L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, I361T, and N362T. PH20 or a variant thereof is characterized in that it comprises a substitution of one or more amino acid residues selected from the group consisting of A, B, C, D, E, F, G, H, H, I, I, L, I, L, G, H ...
[0014] In the present invention, the hyaluronidase contained in the pharmaceutical composition is characterized in that its activity is maintained for a long period of time even under harsh conditions, specifically, the remaining enzyme activity is 20% or more even after 7 days under conditions of 40±2°C.
[0015] The pharmaceutical composition of the present invention may further comprise pharma- ceutically acceptable additives, specifically, one or more selected from the group consisting of buffers and stabilizers.
[0016] The pharmaceutical composition according to the present invention may be used in the form of an injectable dosage form for subcutaneous administration. [Brief description of the drawings]
[0017] [Figure 1] This figure shows the change in hyaluronidase enzyme activity for dosage forms 1, 2, 3, 4, and 5, in which poloxamer and polysorbate were used as surfactants. [Diagram 2] FIG. 1 shows the results of a long-term stability test for dosage form 8. [Diagram 3] This shows the change in hyaluronidase enzyme activity for dosage forms 9, 10, and 11. Figure 3A shows the change in hyaluronidase enzyme activity for dosage forms 9-1, 9-2, 9-3, and 9-4, Figure 3B shows the change in hyaluronidase enzyme activity for dosage forms 10-1, 10-2, 10-3, and 10-4, and Figure 3C shows the change in hyaluronidase enzyme activity for dosage forms 11-1, 11-2, 11-3, and 11-4. [Figure 4] FIG. 1 shows changes in hyaluronidase enzyme activity for dosage forms 12-1, 12-2, 12-3, and 12-4. [Diagram 5] FIG. 1 shows changes in hyaluronidase enzyme activity for dosage forms 13-1, 13-2, 13-3, and 13-4. [Figure 6] FIG. 1 shows changes in hyaluronidase enzyme activity for dosage forms 14-1, 14-2, 14-3, and 14-4. [Figure 7] FIG. 1 shows changes in hyaluronidase enzyme activity for dosage forms 15-1, 15-2, 15-3, and 15-4. [Figure 8] FIG. 1 shows changes in hyaluronidase enzyme activity for dosage forms 16-1 and 16-2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein is one that is well known and commonly used in the art.
[0019] In one embodiment, the present invention relates to a pharmaceutical composition comprising: (a) a drug; (b) hyaluronidase; and (c) a poloxamer-based surfactant.
[0020] In the present invention, the hyaluronidase is used in a concept that includes all hyaluronidases derived from humans or animals, and human hyaluronidase PH20 or a variant thereof is preferred, but is not limited thereto.
[0021] The pharmaceutical composition according to the present invention may be used for the prevention or treatment of diseases, and is preferably characterized in that it is used for subcutaneous administration.
[0022] In particular, in the present invention, the hyaluronidase contained in the pharmaceutical composition is characterized in that its activity is maintained for a long period of time even under harsh conditions, specifically, the residual enzyme activity is 20% or more even after 7 days under conditions of 40±2°C.
[0023] The human PH20 mutant contained in the pharmaceutical composition of the present invention is characterized in that some amino acid residues are substituted in the amino acid sequence of wild-type PH20 (having the amino acid sequence of SEQ ID NO: 1), preferably in the amino acid sequence of mature wild-type PH20 (having a sequence consisting of L36 to S490 of the amino acid sequence of SEQ ID NO: 1), at the alpha helix site and / or the junction site thereof, preferably the alpha helix 8 site (S347 to C381) and / or the junction site between alpha helix 7 and alpha helix 8 (A333 to R346), more preferably the amino acid site between T341 and N363, and most preferably the amino acid sites corresponding to T341 to I361, L342 to I361, S343 to I361, I344 to I361, M345 to I361, or M345 to N363.
[0024] In the present invention, "mature wild-type PH20" means a protein consisting of amino acid residues L36 to S490 of SEQ ID NO: 1, in which the signal peptide M1 to T35 and A491 to L509, which are not related to the substantial function of PH20, are deleted in the amino acid sequence of wild-type PH20 of SEQ ID NO: 1.
[0025] [Table 1]
[0026] In the present invention, the term "PH20 mutant" is used to refer not only to a mutant containing some amino acid residue mutations, preferably amino acid residue substitutions, in the sequence of wild-type human PH20, but also to a mutant containing such amino acid residue substitutions as well as deletion of some amino acid residues at the N-terminus and / or C-terminus, and is used in a manner substantially equivalent to the term "PH20 mutant or a fragment thereof."
[0027] The inventors of the present invention have previously determined that if the amino acid sequence of the alpha helix 8 region and the junction between alpha helix 7 and alpha helix 8 of human PH20 is partially replaced with the amino acid sequence of the alpha helix 8 region and the junction between alpha helix 7 and alpha helix 8 of the highly hydrophilic Hyal1, the enzymatic activity and protein aggregation temperature (Tagg.) at neutral pH are increased, and based on this experimental result, it is possible to provide a new PH20 mutant or a fragment thereof having increased enzymatic activity and thermal stability compared to wild-type PH20.
[0028] Thus, the PH20 mutant contained in the pharmaceutical composition of the present invention has the following amino acid sequence in the amino acid sequence of wild-type PH20 (having the amino acid sequence of SEQ ID NO: 1), preferably the amino acid sequence of mature wild-type PH20 (having a sequence consisting of L36 to S490 of the amino acid sequence of SEQ ID NO: 1): T341S, L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, I361T, and and N363G, more preferably one or more mutations selected from the group consisting of S343E, M345T, K349E, L353A, L354I, N356E, and I361T, preferably an amino acid residue substitution, and most preferably one or more amino acid residue substitutions selected from the group consisting of L354I and N356E, and optionally an N-terminal and / or C-terminal truncation.
[0029] In another aspect, the PH20 mutant of the present invention is further characterized in that one or more amino acid residues are substituted at a site corresponding to the alpha helix site and / or the junction site thereof in the amino acid sequence of wild-type PH20 of SEQ ID NO:1, preferably the alpha helix 8 site (S347 to C381) and / or the junction site between alpha helix 7 and alpha helix 8 (A333 to R346), more preferably at an amino acid site corresponding to T341 to N363, T341 to I361, L342 to I361, S343 to I361, I344 to I361, M345 to I361, or M345 to N363.
[0030] In particular, the PH20 mutant contained in the pharmaceutical composition of the present invention may have the alpha helix 8 site (S347 to C381) and / or the junction site between alpha helix 7 and alpha helix 8 (A333 to R346) of the wild-type PH20, preferably mature wild-type PH20, substituted with some amino acid residues in the amino acid sequence of the corresponding site of Hyal1 having the sequence of SEQ ID NO: 51 (see Tables 2 and 3), but is not limited thereto.
[0031] [Table 2]
[0032] [Table 3]
[0033] More specifically, the PH20 mutant or fragment thereof contained in the pharmaceutical composition of the present invention comprises a substitution of the amino acid residues L354I and / or N356E in the amino acid sequence of wild-type PH20, preferably mature wild-type PH20,
[0034] Furthermore, it is preferable that the amino acid residues are substituted at one or more positions between T341 and N363, particularly at one or more positions selected from the group consisting of T341, L342, S343, I344, M345, S347, M348, K349, L352, L353, D355, E359, I361, and N363, but is not limited thereto.
[0035] More preferably, the amino acid sequence further comprises one or more amino acid residue substitutions selected from the group consisting of T341S, L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, D355K, E359D, I361T, and N363G, but is not limited thereto.
[0036] Preferably, the PH20 mutant or fragment thereof contained in the pharmaceutical composition of the present invention is characterized in that it contains the following amino acid residue substitutions: M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T;
[0037] Furthermore, it is characterized by including one or more amino acid substitutions selected from the group consisting of T341S, L342W, S343E, I344N, and N363G, but is not limited thereto.
[0038] More preferably, the PH20 variant or fragment thereof contained in the pharmaceutical composition of the present invention may include, but is not limited to, any one of the following substitutions selected from the group consisting of: (a) T341S, L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T; (b) L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T; (c) M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T; (d) M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, I361T, and N363G' (e) I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T; and (f)S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T
[0039] In the present invention, an expression in which a one-letter amino acid residue name and a number are written together, such as "S347", means the amino acid residue at each position in the amino acid sequence of SEQ ID NO:1.
[0040] For example, "S347" means that the amino acid residue at position 347 in the amino acid sequence of SEQ ID NO: 1 is serine, and "S347T" means that the serine at position 347 in SEQ ID NO: 1 is replaced with threonine.
[0041] The PH20 mutants contained in the pharmaceutical compositions of the present invention are understood to include mutants in which amino acid residues are conservatively substituted at specific amino acid residue positions.
[0042] As used herein, "conservative substitution" refers to a modification of a PH20 variant that involves replacing one or more amino acids with amino acids having similar biochemical properties that do not result in loss of biological or biochemical function of the PH20 variant.
[0043] A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Classes of amino acid residues having similar side chains have been defined and are well known in the art. These classes include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0044] It is expected that the PH20 variants contained in the pharmaceutical compositions of the invention can have conservative amino acid substitutions and still retain activity.
[0045] Furthermore, the PH20 mutant or a fragment thereof contained in the pharmaceutical composition of the present invention is interpreted to include a PH20 mutant or a fragment thereof having substantially the same function and / or effect as the PH20 mutant or a fragment thereof of the present invention, and having an amino acid sequence homology of 80% or 85% or more, preferably 90% or more, more preferably 95% or more, and most preferably 99% or more.
[0046] The PH20 mutants of the present invention exhibited increased expression in animal cells, increased protein folding rates, and increased thermostability compared to mature wild-type PH20, and furthermore, despite the increased thermostability, their enzymatic activity was increased or similar to that of mature wild-type PH20.
[0047] On the other hand, it is known that the enzymatic activity decreases when some of the C-terminal amino acids, such as S490, of mature wild-type PH20 are further truncated. However, the PH20 mutant of the present invention has an increased thermal stability and increased or similar enzymatic activity compared to mature wild-type PH20, despite having a sequence in which the C-terminal portion of mature wild-type PH20 is further truncated. Furthermore, despite having a sequence in which up to five N-terminal amino acids of mature wild-type PH20 are truncated, it maintains enzymatic activity, demonstrating that the N-terminal P41 residue plays an important role in protein expression and enzymatic activity.
[0048] As a result, the PH20 mutant contained in the pharmaceutical composition of the present invention is characterized by, but is not limited to, the substitution of some amino acid residues at the alpha helix 8 site (S347-C381) and / or the junction site between alpha helix 7 and alpha helix 8 (A333-R346) of wild-type PH20, as well as the deletion of some amino acid residues at the C-terminus and / or N-terminus.
[0049] In one aspect, PH20 or a PH20 mutant contained in a pharmaceutical composition of the present invention has a cleavage occurring before an amino acid residue selected from the group consisting of M1 to P42 at the N-terminus of the amino acid sequence of SEQ ID NO: 1, preferably before an amino acid residue of L36, N37, F38, R39, A40, P41, or P42, and has a deletion of some amino acid residues at the N-terminus, and / or has a cleavage occurring after an amino acid residue selected from the group consisting of V455 to W509 at the C-terminus, preferably after an amino acid residue selected from the group consisting of V455 to W509 at the C-terminus. and characterized in that truncation occurs after an amino acid residue selected from the group consisting of V455 to S490, most preferably V455, C458, D461, C464, I465, D466, A467, F468, K470, P471, P472, M473, E474, T475, E476, P478, I480, Y482, A484, P486, T488, or S490, resulting in the deletion of some amino acid residues at the C-terminus.
[0050] The expression that the cleavage occurs before L36, N37, F38, R39, A40, P41 or P42 at the N-terminus means that the following residues are cleaved and removed: T35, which is the amino acid residue immediately preceding M1 to L36, L36, which is the amino acid residue immediately preceding M1 to N37, N37, which is the amino acid residue immediately preceding M1 to F38, F38, which is the amino acid residue immediately preceding M1 to R39, R39, which is the amino acid residue immediately preceding M1 to A40, A40, which is the amino acid residue immediately preceding M1 to P41, and P41, which is the amino acid residue immediately preceding M1 to P42. However, the meaning that the cleavage occurs before the N-terminus M1 of SEQ ID NO: 1 means that no cleavage occurs at the N-terminus.
[0051] Furthermore, expressions that cleavage occurs after V455, C458, D461, C464, I465, D466, A467, F468, K470, P471, P472, M473, E474, T475, E476, P478, I480, Y482, A484, P486, T488, or S490 at the C-terminus refer to the same as those in SEQ ID NO:1, respectively. This means that cleavage begins at the amino acid residue next to V455, C458, D461, C464, I465, D466, A467, F468, K470, P472, M473, E474, T475, E476, P478, I480, Y482, A484, P486, T488, or S490 in the sequence and is removed. For example, cleavage next to S490 means that cleavage occurs between S490 and A491.
[0052] Preferably, the human PH20 mutant contained in the pharmaceutical composition of the present invention may be selected from the group consisting of the amino acid sequences of SEQ ID NO: 5 to SEQ ID NO: 50, and more preferably may have the amino acid sequence of SEQ ID NO: 44, but is not limited thereto. The sequences of the amino acids substituted or truncated in the PH20 mutants prepared in the specific examples of the present invention are as shown in Table 4.
[0053] [Table 4] JPEG2024541973000006.jpg246170JPEG2024541973000007.jpg251170JPEG202 4541973000008.jpg246170JPEG2024541973000009.jpg245170JPEG2024541973 000010.jpg247170JPEG2024541973000011.jpg247170JPEG2024541973000012. jpg247170JPEG2024541973000013.jpg246170JPEG2024541973000014.jpg78170
[0054] Meanwhile, previous studies have reported that the enzymatic activity of wild-type human PH20 changes depending on the cleavage position of the amino acid residues located at the C-terminus. In the present invention, however, a specific alpha helix that constitutes the secondary structure of human PH20 was replaced with the alpha helix of another human hyaluronidase to produce human PH20 mutants that are more stable than wild-type human PH20. These mutants are characterized by having a certain level of enzymatic activity regardless of the C-terminal cleavage position, because the interaction between the substituted alpha helix domain and other secondary structures of PH20 exhibits a different behavior from that of wild-type PH20.
[0055] Furthermore, in the present invention, we aimed to improve the expression of recombinant human PH20 or its mutants by using signal peptides of other proteins that show high protein expression levels in animal cells, rather than the inherent signal peptide of human PH20 or its mutants.
[0056] Thus, in yet another aspect, the PH20 mutant contained in the pharmaceutical composition of the present invention is characterized in that, instead of the signal peptide of wild-type PH20 M1 to T35, it comprises a signal peptide derived from human hyaluronidase-1 (Hyal1), human growth hormone, or human serum albumin at the N-terminus, and is preferably characterized in that it comprises a signal peptide derived from human growth hormone having the amino acid sequence MATGSRTSLLLAFGLLCLPWLQEGSA according to SEQ ID NO: 2, a signal peptide derived from human serum albumin having the amino acid sequence MKWVTFISLLFLFSSAYS according to SEQ ID NO: 3, or a signal peptide derived from human Hyal1 having the amino acid sequence MAAHLLPICALFLTLLDMAQG according to SEQ ID NO: 4, as shown in Table 5, but is not limited thereto.
[0057] [Table 5]
[0058] Among the PH20 mutants contained in the pharmaceutical composition of the present invention, the mutant with a 6xHis-tag attached to the C-terminus was named HM, and the mutant without the 6xHis-tag was named HP. In addition, the mature wild-type PH20 (L36-S490) with a 6xHis-tag attached to the C-terminus was named WT, and the mature wild-type PH20 (L36-Y482) without the 6xHis-tag and truncated at the C-terminus next to Y482 was named HW2.
[0059] HP46 (sequence number 44) is a mutant of human PH20 in which the amino acids of alpha helix 8 of human PH20 and the amino acid sequence of the junction between alpha helix 7 and alpha helix 8 are replaced with the amino acid sequence of Hyal1, the N-terminus is truncated at F38, and the C-terminus is truncated after F468, after modeling the protein structure using Hyal1 (PDB ID: 2PE4) (Chao et al., 2007), a human hyaluronidase with a known tertiary protein structure.
[0060] The pharmaceutical composition according to the present invention contains PH20 or a PH20 mutant at least 50 units / mL, preferably 100 to 20,000 units / mL, more preferably about 150 to 18,000 units / mL, even more preferably 1,000 to 16,000 units / mL, and most preferably 1,500 to 12,000 units / mL.
[0061] Drugs contained in the pharmaceutical composition of the present invention include, but are not limited to, protein drugs, antibody drugs, small molecules, cell therapy agents such as aptamers, RNAi, antisense, CAR (chimeric antigen receptor)-T or CAR-NK (Natural Killer), etc., and any drug currently being used in clinical trials or under development can be used as well as those currently being commercially used.
[0062] As the above drug, preferably, a protein drug or an antibody drug may be used.
[0063] The "protein drug" contained in the pharmaceutical composition of the present invention is a drug composed of amino acids and exerts an effect of treating or preventing a disease through the activity of the protein, and means a drug composed of a protein other than an antibody drug, and may be selected from the group consisting of cytokines, therapeutic enzymes, hormones, soluble receptors and their fusion proteins, insulin or its analogues, BMP (Bone Morphogenetic Protein), EPO (erythropoietin), and serum derived proteins, but is not limited thereto.
[0064] The cytokine contained in the pharmaceutical composition of the present invention may be selected from the group consisting of interferon, interleukin, CSF (colony stimulating factor), TNF (tumor necrosis factor), TGF (tissue growth factor), etc., but is not limited thereto. The therapeutic enzyme may be, but is not limited to, beta-glucocerebrosidase, agalsidase β, etc.
[0065] Examples of cytokines and their analogs include, but are not limited to, Oprelvekin, Peginterferon Beta-1a, Pegilodecakin, Rezpegaldesleukin, SAR444245, GO-203-2c, Dekavil, Nemvaleukin alfa, Efavaleukin alfa, Efineptakin alfa, Onfekafusp alfa, Bifikafusp alfa, and Lerodalcibep.
[0066] The soluble receptor contained in the pharmaceutical composition according to the present invention means the extracellular domain of a receptor, and the fusion protein means a protein in which the soluble receptor is fused with the Fc region of an antibody or the like. The soluble receptor is a soluble form of a receptor to which a disease-related ligand binds, and includes a form in which the Fc region is fused with a soluble TNF-α receptor (e.g., a product with the ingredient name Etanercept and similar forms), a form in which the Fc region is fused with a soluble VEGF receptor (e.g., a product with the ingredient name Aflibercept, Conbercept, or OPT-302 and similar forms), a form in which the Fc region is fused with a soluble CTLA-4 receptor (e.g., abatacept and similar forms), and a form in which the Fc region is fused with a soluble VEGF receptor (e.g., a product with the ingredient name Aflibercept, Conbercept, or OPT-302 and similar forms). tacept or Belatacept, and similar forms), interleukin soluble receptors fused with Fc domains (e.g., Rilonacept or Inbakicept, and similar forms), LFA3 soluble receptors fused with Fc domains (e.g., Alefacept, and similar forms), signal regulatory protein alpha (SAR) interacting with CD47 (SAR), Examples include, but are not limited to, forms in which the Fc region is fused to SIRPalpha (e.g., products with the active ingredient names Evorpacept, Ontorpacept, or TTI-622, and forms similar thereto), products with the active ingredient names Sotatercept, Dalantercept, Acazicolcept, or Dazodalibep, and forms similar thereto.
[0067] The hormone contained in the pharmaceutical composition according to the present invention means a hormone or an analog thereof that is injected from the outside of the body for the treatment or prevention of a disease caused by hormone deficiency or the like, and examples thereof include, but are not limited to, human growth hormone, estrogen, progesterone, etc.
[0068] The plasma-derived proteins contained in the pharmaceutical composition of the present invention refer to all proteins present in plasma, including those extracted from plasma and those produced by recombinant means, and examples thereof may include, but are not limited to, fibrinogen, von Willebrand Factor, albumin, thrombin, FII (Factor II), FV (Factor V), FVII (Factor VII), FVIII (Factor VIII), FIX (Factor IX), FX (Factor X) and FXI (Factor XI).
[0069] The antibody drug contained in the pharmaceutical composition of the present invention may be a monoclonal antibody drug or a polyclonal antibody drug.
[0070] The monoclonal antibody drug according to the present invention refers to a protein containing a monoclonal antibody or a monoclonal antibody fragment that can specifically bind to an antigen associated with a specific disease. The monoclonal antibody also includes a bibody, and the protein containing a monoclonal antibody or a fragment thereof is used to include an ADC (Antibody-drug conjugate).
[0071] Antigens associated with specific diseases include 4-1BB, 5T4, integrin, activin, amyloid beta, angiopoietin (angiopoietin 1 or 2), angiopoietin analog 3, B cell maturation antigen (BCMA), B-cell activating factor (B-cell activating factor), and cytotoxic factor (C-cell activating factor). factor, BAFF), B7-H3, complement 5, CCR4, CCR5, CCL11, CD2, CD3, CD4, CD6, CD11a, CD16A, CD19, CD20, CD22, CD25, CD27, CD28, CD30, CD32B, CD33, CD38, CD40, CD45, CD46, CD47, CD52, CD56, CD62, CD70, CD73, CD74, CD79b, CD80, CD105, CD123, CD154, CD166, CD262, CD278, CD319, CD326, Carcinoembryonic antigen,CEA), CGRP, Claudin-18, c-Met, CSF-1, CSF-1 receptor, CTLA4, DLL3, EGF receptor, hemophilia factor, Fc receptor, FGF23, folate receptor, GD2, glucocorticoid-induced TNF receptor (GITR), glypican 3, GM-CSF, HER2, HER3, Hepatocyte Growth Factor Factor,HGF), interferon receptor, interferon gamma, IgE, IGF-1 receptor, interleukin 1, interleukin 2 receptor, interleukin 4, interleukin 4 receptor, interleukin 5, interleukin 5 receptor, interleukin 6, interleukin 6 receptor, interleukin 8, interleukin 12 / 23, interleukin 13, interleukin 17A, interleukin 17 receptor A, interleukin 23, interleukin 31 receptor, interleukin 36 receptor, lymphocyte-activation gene 3,LAG3), Lysyl oxidase homolog 2 (LOXL2), Mesothelin, Mucin-1, Mucin-16, Netin-4, Nerve Growth Factor (NGF), OX40, Proprotein Convertase Subtilisin / Kexin type 9 (PCSK9), PD-1, PD-L1, Phospholipase C, Receptor activator of nuclear factors kappa B ligand (RANKL), Tyrosine-protein kinase transmembrane receptor (ROR1), Sialic acid binding ig-like lectin 15 (Siglec-15), Transforming growth factor beta (TGF-β) Examples of such proteins include, but are not limited to, TGFβ (T-cell innunoreceptor with immunoglobulin and ITIM domain), T cell immunoglobulin and mucin-domain containing-3 (Tim-3), tissue factor, tissue factor pathway inhibitor (TFPI), TORP-2, tumor necrosis factor (TNF), thymic stromal lymphopoietin (TSLB), colony stimulating factor 1 receptor (CSF1R), vascular endothelial growth factor (VEGF), VEGF receptor, and vWF (von Willebrand Factor).
[0072] In addition, proteins including monoclonal antibodies and monoclonal antibody fragments against antigens associated with specific diseases, bi / multispecific antibodies, and antibody-drug conjugates may be exemplified by, but are not limited to, the following drugs:
[0073] Proteins containing monoclonal antibodies and monoclonal antibody fragments include ADG 106.EU101, LVGN6051, Urelumab, Utomilumab, Bebtelovimab, Aducanumab, Bapinezumab, Crenezumab, Donanemab, Gantenerumab, Lecanemab, Solanezumab, and the like. zumab, Nesvacumab, Enoblituzumab, Omburtamab, Belimumab, Ianalumab, Tabalumab, Bertilimumab, Mogamulizumab, Leronlimab, Siplizumab , Foralumab, Muromonab-CD3, Otelixizumab, Teplizumab, Ibalizumab, Tregalizumab, Zanolimumab, Itolizumab, Epalizumab, Inebilizumab , Tafasitamab, Tositumomab, Ocrelizumab, Ofatumutumab, Ublituximab, Veltuzumab, Epratuzumab, Basiliximab, Daclizumab, Varlilumab, Lulizumab pegol, Iratumumab, BI-1206, Lintuzumab, Daratumumab, Felzartamab, GEN3014, Isatuximab,Mezagitamab, CDX-1140, Bleselumab, Dacetuzumab, Iscalimab, Lucatumumab, Mitazalimab, SEA-CD40, Sotigalimab, SAR441344, Tegoprubart, Dapirolizumab pegol, I-131 I-131-Apamistamab, AO-176, Ligufalimab, Magrolimab, Alemtuzumab, Crizanlizumab, Inclacumab, Cusatuzumab, Oleclumab, Milatuzumab mab), Galiximab, Carotuximab, Adecatumumab, Eptinezumab, Erenumab, Fremanezumab, Galcanezumab, TST001, ZL-1211, Zolbetuximab, Onartuzumab ( Onartuzumab, Eculizumab, Pozelimab, Ravulizumab, Lacnotuzumab, PD-0360324, AMB-051, Axatilimab, Cabiralizumab, Emactuzumab, BA3071, Ipilimumab imumab, Quavonlimab, Tremelimumab, Zalifrelimab, Cetuximab, Depatuxizumab, Futuximab, Imgatuzumab, Matuzumab, Modotuximab,Necitumumab, Nimotuzumab, Panitumumab, Tomuzotuximab, Zalutumumab, MK-2060, Batoclimab, Nipocalimab, Rozanolixizumab, Burosumab, Farletuzumab, Dinutuximab, Dinutuximab beta beta), Naxitamab, BMS-986156, Ragifilimab, Gimsilumab, Lenzilumab, Mavrilimumab, Namilumab, Otilima, Plonmarlimab, Codrituzumab Drituzumab, Margetuximab, Pertuzumab, Trastuzumab, HMBD-001, Patritumab, Seribantumab, Durigotuzumab, Ficlatuzumab, Rilotuzumab lotumumab, Alomfilimab, Anifrolumab, Emapalumab, FB825, Ligelizumab, Omalizumab, Cixutumumab, Dalotuzumab, Figitumumab, Ga Ganitumab, Teprotumumab, Bermekimab, Canakinumab, Gevokizumab, Briakinumab, Ustekinumab, Anrukinzumab, Cendakimab,Lebrikizumab, Tralokinumab, Brodalumab, Bimekizumab, Ixekizumab, Secukinumab, Brazikumab, Guselkumab, Mirikizumab, Risankizumab, Tildrakizumab, Nemolizumab, Indiragi Imsidolimab, Spesolimab, Pascolizumab, CBP201, Dupilumab, Depemokimab, Mepolizumab, Reslizumab, Benralizumab, Clazakizumab, Olokizumab, Siltuximab, Sirukumab, Ziltibet Ziltivekimab, Levilimab, Sarilumab, Sarilumab, Tocilizumab, HuMax-IL8, Abituzumab, Favezelimab, Fianlimab, GSK2831781, Ieramilimab, INCAGN02385, Relatlimab, Simtuzumab, Avagovomab (Abagovomab), Oregovomab, Tanezumab, BMS-986178, GSK3174998, INCAGN01949, Ivuxolimab, Rocatinlimab, Tavolimab, Telazorlimab, Vonlerolizumab, Alirocumab, Bococizumab, Ebronucimab,Evolocumab, Frovocimab, Ongericimab, Tafolecimab, Dostarlimab, Balstilimab, Camrelizumab, Cemiplimab, Geptanolimab, MEDI0680, Nivolumab, Pembrolizumab, Penpulimab mab, Pidilizumab, Prolgolimab, Retifanlimab, Sasanlimab, Serplulimab, Sintilimab, Spartalizumab, Tislelizumab, Toripalimab, Ezabenlimab, Zimberelimab, Atezolizumab olizumab, Avelumab, Cosibelimab, Sugemalimab, Durvalumab, IMC-001, Envafolimab, Suvratoxumab, Denosumab, Zilovertamab, NC318, Elotuzumab, NIS793, BMS-986207, Domvanalimab, EOS-44 8. Etigilimab, Ociperlimab, Tiragolumab, Vibostolimab, Surzebiclimab, Cobolimab, Sabatolimab, TQB2618, Concizumab, Marstacimab, Adalimumab, Golimumab, Infliximab,Certolizumab pegol, Conatumumab, Tigatuzumab, Tezepelumab, Gatipotuzumab, Cabiralizumab, Bevacizumab, These include, but are not limited to, brolucizumab, ranibizumab, olinvacimab, icrucumab, ramucirumab, caplacizumab, abrilumab, etrolizumab, vedolizumab, intetumumab, and natalizumab.
[0074] Bi / multispecific antibodies and antibody-like proteins include DSP107, RO7122290, Cinrebafusp alfa, GEN1042, Rozibafusp alfa, GEN1044, Obrindatamab, GEN1047, Elranatamab, Linvoseltamab,Teclistamab, Epcoritamab, Glofitamab, Mosunetuzumab, Odronextamab, Flotetuzumab, Vibecotamab, Catumaxomab, Civita Cibisatamab, TAK-186, Talquetamab, Ubamatamab, NVG-111, Emfizatamab, HPN536, AFM13, Blinatumomab, ISB1442, CPO107, AFM24, Amivatamab, MCLA-1 29, SI-B001, Emicizumab, Mim8, Zenocutuzumab, Zanidatamab, Tibulizumab, GI-101, Vobarilizumab, REGN5668, HX009, Cadonilimab, Vudalimab ab), EMB-02, RO7247669, Tebotelimab, IBI318, AZD2936, AZD7789, RO7121661, Ivonescimab, IBI322, ES101, GEN1046, PRS-344, Erfonrilimab, FS118, Bintrafusp alfa, HB0036, HLX301, NM21-1480, Ozoralizumab, Vanucizumab, Navicixizumab, IBI302, and the like, but are not limited to these.
[0075] Antibody-drug conjugates include Naptumomab estafenatox, Belantamab mafodotin, DS-7300, MGC018, Pivekimab sunirine, Praluzatamab ravtansine, Coltuximab ravtansine, Denintuzumab mafodotin, Loncastuximab tesirine, Ibritumomab tiuxetan, Inotuzumab ozogamicin, ozogamicin, Epratuzumab-cys-tesirine, Moxetumomab pasudotox, Brentuximab vedotin, Gemtuzumab ozogamicin, Vadastuximab talirine, STI-6129, FOR46, Lorvotuzumab mertansine, Polatuzumab vedotin, Tusamitamab ravtansine, Telisotuzumab vedotin, rovalpituzumab tesirine, depatuxizumab mafodotin, farletuzumab ecteribulin, mirvetuximab soravtansine, ARX788, trastuzumab deruxtecan, trastuzumab duocarmazine, A166, trastuzumab emtansineExamples of anti-cancer drugs include, but are not limited to, Disitamab vedotin, Pertuzumab zuvotolimod, Patritumab Deruxtecan, Anetumab ravtansine, BMS-986148, Enfortumab vedotin, NBE-002, MRG004, ABBV-3373, and Sacituzumab Govitecan.
[0076] The content of the antibody pharmaceutical in the pharmaceutical composition according to the present invention may be 5 to 500 mg / mL, preferably 20 to 200 mg / mL, more preferably 100 to 150 mg / mL, and most preferably 120±18 mg / mL, for example, about 110 mg / mL, about 120 mg / mL, or about 130 mg / mL.
[0077] The polyclonal antibody contained in the pharmaceutical composition of the present invention is preferably a serum antibody such as immune globulin extracted from plasma, but is not limited thereto.
[0078] Small molecule compounds can be used for any drug that requires a fast effect for preventive or therapeutic purposes. For example, morphine system activation control can be used (Thomas et al., 2009). In addition, when used as a treatment for tissue necrosis caused by anticancer drugs, they can be used alone or together with antidote drugs such as vinca alkaloids and taxanes (Kreidieh et al., 2016).
[0079] The pharmaceutical composition or dosage form according to the present invention is characterized in that it contains a surfactant, particularly a poloxamer-based surfactant. Poloxamer is a non-ionic surfactant that has been certified as a generally recognized as safe substance (GRAS) by the US FDA, and is known to generally cause no reaction even at a daily dose of 3 g in acute chest pain (Zarrintaj et al., 2020). Poloxamer-based surfactants are known to have anticancer effects and are also used as components of hydrogels, and are added at a concentration of 0.1 to 0.5% during cell culture to protect cells from air bubbles. Poloxamer-based surfactants have a structure such as chemical formula (1) or chemical formula (2), and are composed of polyethylene oxide (polyethylene oxide, poly-EO) and polypropylene oxide (poly-PO), and are named according to the content of each EO chain and PO chain. The mass content per molecule of the EO chain is selected from the range of 10% to 80%, and the mass per molecule of the PO chain is selected from the range of 950 to 4000 daltons.
[0080] [ka]
[0081] In the above chemical formula (1) and chemical formula (2), x has a value of 2 to 130, and y has a value of 15 to 67, preferably, x has a value of 10 to 60, and y has a value of 20 to 40, more preferably, x has a value of 10 to 60, and y has a value of 20 to 40, and most preferably, x has a value of 38, and y has a value of 29.
[0082] Preferably, the poloxamer surfactant may be poloxamer 188, but is not limited thereto. Poloxamer 188 is also called Pluronic F68, and refers to a case where the EO chain content is 80% and the molecular weight of the PO chain is 1,750 Daltons, in which case the molecular weight is 8,750 Daltons. The micelle concentration (CMC) of this poloxamer 188 is known to be 0.04 mM (~0.03%). This value is far higher than the 0.006% and 0.0012% of polysorbate 20 and polysorbate 80, which are similar nonionic surfactants.
[0083] Poloxamer 188 is used in many antibody and protein drugs. TM (Roche) 0.05%, Gazyva TM (Roche-Sobi, Sweden) 0.02%, Hemlibra TM (Roche) 0.05%, Danyelza TM (Y-mAbs) 0.15%, Orencia TM (BMS) at 0.8%, Nuwiq (Octaphama) at 0.12%, and Accretropin (Cangene) at 0.2% ( Strichley & Lambert, 2021 ).
[0084] The concentration of the poloxamer surfactant, preferably poloxamer 188, in the pharmaceutical composition of the present invention may be, but is not limited to, 0.001% to 1.5% (w / v), preferably 0.01% to 1.0% (w / v), more preferably 0.02% to 0.8% (w / v), and most preferably 0.05% to 0.5% (w / v).
[0085] In one aspect, the invention relates to a pharmaceutical composition comprising hyaluronidase and a poloxamer-based surfactant without a drug.
[0086] Furthermore, the pharmaceutical composition of the present invention may further comprise one or more substances selected from the group consisting of a buffering agent and a stabilizing agent.
[0087] The buffer contained in the composition according to the present invention can be any buffer that provides a pH of 4 to 8, preferably 5 to 7. Examples of the buffer include malate, formate, citrate, acetate, propionate, pyridine, piperazine, cacodylate, succinate, 2-(N-morpholino)ethanesulfonic acid (MES), histidine, Tris, bis-Tris, phosphate, ethanolamine, carbonate, 2-ethanesulfonic acid (piperazine-N,N'-bis(2-ethanesulfonic Preferred is one or more selected from the group consisting of N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-(N-morpholino)propanesulfonic acid (MOPS), HEPES (hydroxyethyl piperazine ethyl sulfonic acid), pyrophosphate, and triethanolamine, and more preferred is a histidine buffer, for example, L-histidine / HCl or an acetate buffer, but is not limited thereto.
[0088] The concentration of the buffer may be 0.001 to 200 mM, preferably 1 to 50 mM, more preferably 5 to 40 mM, and most preferably 10 to 30 mM.
[0089] As the stabilizer in the composition of the present invention, any substance commonly used in the art for the purpose of stabilizing proteins can be used, and preferred examples thereof include one or more substances selected from the group consisting of carbohydrates, sugars or hydrates thereof, sugar alcohols or hydrates thereof, and amino acids.
[0090] The carbohydrate, sugar or sugar alcohol used as the stabilizer is at least one selected from the group consisting of trehalose or a hydrate thereof, sucrose, saccharin, glycerol, erythritol, threitol, xylitol, arabitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, polyglycitol, cyclodextrin, hydroxypropyl beta-cyclodextrin, and glucose;
[0091] The amino acid may be one or more selected from the group consisting of glutamine, glutamic acid, glycine, lysine, cylysine, leucine, methionine, valine, serine, selenomethionine, citrulline, arginine, asparagine, aspartic acid, ornithine, isoleucine, taurine, theanine, threonine, tryptophan, tyrosine, phenylalanine, proline, pyrrolysine, histidine, and alanine, but is not limited thereto. Preferably, methionine may be used.
[0092] The concentration of the sugar or sugar alcohol used as a stabilizer in the pharmaceutical composition of the present invention is 0.001 to 500 mM, preferably 100 to 300 mM, more preferably 150 to 250 mM, and most preferably 180 to 230 mM, and specifically may be about 210 mM.
[0093] Furthermore, the concentration of the amino acid used as a stabilizer in the pharmaceutical composition according to the present invention may be 1 to 100 mM, preferably 3 to 30 mM, more preferably 5 to 25 mM, and most preferably 7 to 20 mM, specifically about 8 to 15 mM.
[0094] In one specific example, the pharmaceutical composition according to the present invention may contain 50 to 350 mg / mL of an antibody, such as an anti-HER2 antibody or an immune checkpoint antibody, 100 to 20,000 units / mL of a PH20 mutant, 0.001% to 1.5% (w / v) of a poloxamer-based surfactant, 0.001 to 200 mM of a histidine buffer providing a pH of 5.5±2.0, and 10 to 400 mM of α,α-trehalose, and may optionally further contain 1 to 50 mM of methionine.
[0095] In a more specific embodiment, the pharmaceutical composition according to the present invention may contain 120±18 mg / mL anti-HER2 antibody or immune checkpoint antibody, 1,500-12,000 units / mL of a PH20 mutant, 0.1%-0.5% (w / v) poloxamer surfactant, 10-30 mM histidine buffer providing a pH of 5.5±2.0, 180-230 mM α,α-trehalose, and may optionally further contain 8-15 mM methionine.
[0096] The pharmaceutical composition according to the present invention can be administered by intravenous injection, subcutaneous injection, intramuscular injection, peritoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, and intrarectal administration, and is preferably administered subcutaneously by subcutaneous injection, and more preferably used in the form of an injection dosage form for subcutaneous injection administration.
[0097] Thus, in another aspect, the present invention provides a formulation, preferably a formulation for subcutaneous administration, comprising a pharmaceutical composition according to the invention.
[0098] The dosage form for subcutaneous administration is preferably an injection dosage form, which may be provided in a ready-to-injection form without an additional dilution process, and may be provided in a pre-filled syringe, a glass ampoule, a plastic container, a wearable device, or an auto-injector.
[0099] Wearable devices are also called wearable injectors, and examples of products that may be used include, but are not limited to, products from West, Enable Injections, Ypsomed, Weibel CDS, Subcuject, Eitan Medical, and Sonceboz (Wearable Injectors, 2019).
[0100] The present invention also relates to a method for treating a disease using a pharmaceutical composition or dosage form according to the present invention.
[0101] There are no particular limitations on the diseases that can be treated with the pharmaceutical composition or dosage form of the present invention, and any disease that can be treated with a drug used in combination with PH20 or a PH20 mutant of the present invention is possible.
[0102] Diseases treatable by the pharmaceutical composition or dosage form of the present invention may be exemplified by cancer, autoimmune diseases, etc., but are not limited thereto.
[0103] Cancer or carcinoma treatable by the pharmaceutical composition or dosage form of the present invention is not particularly limited, and includes both solid cancer and blood cancer. Examples of such cancer may be selected from the group consisting of skin cancer such as melanoma, liver cancer, hepatocellular carcinoma, stomach cancer, breast cancer, lung cancer, ovarian cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer, colon cancer, cervical cancer, brain cancer, prostate cancer, bone cancer, thyroid cancer, parathyroid cancer, kidney cancer, esophageal cancer, biliary tract cancer, testicular cancer, rectal cancer, head and neck cancer, cervical cancer, ureter cancer, osteosarcoma, neuroblastoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma, and glioma. Preferably, the cancer treatable by the pharmaceutical composition or dosage form of the present invention may be selected from the group consisting of stomach cancer, colon cancer, breast cancer, lung cancer, and kidney cancer, but is not limited thereto.
[0104] The autoimmune disease treatable by the pharmaceutical composition or dosage form of the present invention may be selected from the group consisting of, but is not limited to, rheumatoid arthritis, asthma, psoriasis, multiple sclerosis, allergic rhinitis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, type I diabetes, inflammatory bowel disease (IBD), and atopic dermatitis.
[0105] The present invention also provides a method for treating a disease, comprising administering the pharmaceutical composition or dosage form of the present invention to a subject in need of treatment, and further provides a use of the pharmaceutical composition or dosage form of the present invention for producing a medicament for treating a disease.
[0106] Unless otherwise specified, technical and scientific terms used in the present invention have the meanings commonly understood by those having ordinary knowledge in the technical field to which this invention belongs. In addition, repeated explanations of the same technical configurations and functions as those in the past will be omitted. EXAMPLES
[0107] The present invention will be described in more detail below with reference to examples. It will be apparent to those skilled in the art that these examples are merely for the purpose of illustrating the present invention and are not intended to limit the scope of the present invention.
[0108] Example 1. Dosage Form Development: Stability Study of Subcutaneous Trastuzumab Dosage Form Containing Poloxamer 188
[0109] As shown in Table 6 below, five types of Trastuzumab subcutaneous injection dosage forms were manufactured. Formulations 1 to 5 all contain 120 mg / mL trastuzumab, and are composed of 20 mM histidine / histidine-HCl (pH 5.5), 210 mM trehalose, and 2000 units / mL hyaluronidase. Formulations 1 to 3 use HP46 as hyaluronidase, while Formulations 4 and 5 use wild-type recombinant PH20 (rHuPH20). In addition, all formulations except Formulation 3 contain 10 mM methionine. Formulations 1 and 4 contain 0.04% polysorbate 20, and Formulations 2, 3, and 5 contain 0.2% poloxamer 188 as surfactants.
[0110] [Table 6]
[0111] To confirm the stability of each formulation, they were stored under harsh conditions of 40±2℃ and 60±5% relative humidity (RH), and then removed at intervals of 0, 1, 4, and 7 days for the following analyses.
[0112] B. Content measurement using a spectrophotometer
[0113] The change in protein concentration during the stability period was analyzed using a spectrophotometer. After diluting the sample with distilled water to a concentration of 0.4 mg / mL, the protein absorbance was measured at 280 nm using a spectrophotometer. In Table 7, the protein content is shown as a relative content based on the first test day.
[0114] [Table 7]
[0115] B. Investigation of impurity ratio of trastuzumab using size-exclusion chromatography
[0116] For size exclusion chromatography analysis, a Shimadzu Prominence HPLC system was used with TSK-gel G3000SWXL (7.8X300mm, 5μm) and a TSK guard column (6.0×4.0mm, 7μm). 0.2M potassium phosphate (pH 6.2) containing 0.25M potassium chloride was used as the mobile phase. The analysis was performed for 35 minutes in isocratic separation mode at a flow rate of 0.5mL / min. The sample was diluted with the analysis solvent to a final concentration of 10mg / mL, and 20μL was injected into the HPLC column, after which the absorbance of the column eluate was recorded at 280nm. The impurity ratio of trastuzumab was calculated from the HPLC chromatogram and is shown in Table 8.
[0117] [Table 8]
[0118] C. IEX chromatographic measurement for dosage forms 1 to 5
[0119] For the IEX chromatography analysis, a Shimadzu Prominence HPLC system and columns such as TSKgel CM-STAT (4.6 x 100 mm, 7 μm) and TSKgel guard gel CMSTAT (3.2 mm lD x 1.5 cm) were used. Mobile phase A was 10 mM sodium phosphate (pH 7.5), and mobile phase B was 10 mM sodium phosphate (pH 7.2) containing 0.1 M NaCl. Analysis was performed for 55 minutes at a flow rate of 0.8 mL / min with a linear concentration gradient of 0 to 30% mobile phase B. The sample was diluted with mobile phase A to a final concentration of 1.0 mg / mL, and 80 μL of the sample was injected into the HPLC, after which the absorbance of the column eluate was recorded at 280 nm. The monomer ratio of trastuzumab was calculated from the HPLC chromatogram and is shown in Table 9.
[0120] [Table 9]
[0121] 2. Insoluble particle measurement for dosage forms 1 to 5
[0122] For insoluble particulate measurement, 1 mL of sample was diluted to 30 mL in the measuring device and measured according to the method described in the General Test Method for Injectables, and the results are shown in Table 10. The standard for the General Test Method for Insoluble Particulates for Injectables is that the number of particles 10 μm or larger (NLT 10 μm) must be 6,000 or less, and the number of particles 25 μm or larger (NLT 25 μm) must be 600 or less.
[0123] [Table 10]
[0124] E. Hyaluronidase enzyme activity measurement for dosage forms 1 to 5
[0125] Microturbidimetric assay, which measures enzyme activity, measures the degree to which hyaluronic acid remaining in the reaction solution binds to acidified albumin (BSA) to form aggregates by measuring absorbance. When hyaluronic acid is hydrolyzed by hyaluronidase, the amount of hyaluronic acid bound to albumin decreases, resulting in a decrease in absorbance. As a standard, dilute BTH (Sigma) to 1, 2, 5, 7.5, 10, 15, 20, 30, 50, and 60 units / mL and prepare in each tube. Dilute the sample with enzyme diluent buffer (20 mM Tris·HCl, pH 7.0, 77 mM NaCl, 0.01% (w / v) bovine serum albumin) to 100X, 300X, 600X, 1200X, and 2400X and prepare in each tube. In a new tube, dilute the 3 mg / mL hyaluronic acid solution 10 times to a concentration of 0.3 mg / mL, so that the volume of each tube is 180 μL. Add 60 μL of a sample containing hyaluronidase to the diluted hyaluronic acid solution, mix, and react at 37°C for 45 minutes. After the reaction is complete, add 50 μL of the reacted enzyme and 250 μL of acidic albumin solution to each well of a 96-well plate, shake for 10 minutes, and then measure the absorbance at 600 nm using a spectrophotometer.
[0126] The test results for each dosage form are shown in Figure 1.
[0127] From the results of Example 1, it was found that there was no difference in the stability of the antibody in each of the five formulations, since there was no significant change in sub-visible particles, content, purity, or charge variants. However, the 0.2% poloxamer 188 formulation showed no significant difference in antibody stability compared to the 0.04% polysorbate 20 formulation, but the hyaluronidase enzyme activity was much higher and maintained for a long period of time.
[0128] Furthermore, when the initial hyaluronidase enzyme activity was the same, the results showed that the enzyme activity was better maintained in a formulation containing HP46 than in a formulation containing rHuPH20.
[0129] Example 2. Dosage Form Development: Severe Stability Test of Hyaluronidase-Only Dosage Form
[0130] An experiment was conducted to examine the stability of a hyaluronidase-only formulation that does not contain other drugs. A hyaluronidase-only formulation was prepared as shown in Table 11, and the enzyme activity was examined under harsh conditions of 40±2°C and 60±5% relative humidity as shown in Table 12.
[0131] [Table 11]
[0132] [Table 12]
[0133] As shown in Table 12, it was confirmed that the enzyme activity was similarly well maintained in the pH range of 6 to 7 in both formulations 6 and 7.
[0134] Example 3. Dosage Form Development: Long-term Stability Test of Hyaluronidase-Only Dosage Form
[0135] An experiment was conducted to investigate the long-term stability of hyaluronidase alone, not mixed with other protein therapeutics. Hyaluronidase alone (formulation 8) was prepared with 3,000 units / mL hyaluronidase (HP46), 10 mM sodium phosphate, 145 mM NaCl, 10 mM methionine, 0.1% human serum albumin, 0.02% polysorbate 80, pH 7.0, and it was confirmed whether the appearance, pH, osmolality, endotoxin content, sterility, particulated matter (visible), particulated matter (subvisible), potency (enzyme activity) / identity, extractable volume, and container-closure integrity changed at 5±3℃, which is the long-term storage condition, as shown in Figure 2.
[0136] Example 4. Dosage Form Development: Stability Test of Trastuzumab Subcutaneous Injection Dosage Forms by Surfactant Type
[0137] As shown in Table 13, Trastuzumab subcutaneous injection formulations were prepared according to the type and concentration of surfactant, and the stability of each formulation under harsh conditions was confirmed. Each formulation contained 120 mg / mL trastuzumab and was basically composed of 20 mM histidine / histidine-HCl (pH 5.5), 210 mM trehalose, 10 mM methionine, and 2000 units / mL hyaluronidase. HP46 was used as the hyaluronidase. To this basic composition, dosage forms 9-1, 9-2, 9-3, and 9-4 are dosage forms to which polysorbate 20 has been added at 0.005%, 0.01%, 0.1%, and 0.2%, respectively; dosage forms 10-1, 10-2, 10-3, and 10-4 are dosage forms to which polysorbate 80 has been added at 0.005%, 0.01%, 0.1%, and 0.2%, respectively; and dosage forms 11-1, 11-2, 11-3, and 11-4 are dosage forms to which poloxamer 188 has been added at 0.005%, 0.01%, 0.1%, and 0.2%, respectively.
[0138] [Table 13]
[0139] The stability of each Trastuzumab subcutaneous injection dosage form listed in Table 13 was confirmed under the harsh conditions of 40±2°C and 60±5% relative humidity. The change in content was measured by the content method using a spectrophotometer in Example 1 (a) and is shown in Table 14. The change in IEX chromatography was measured by the IEX chromatography method in Example 1 (c) and is shown in Table 15. The change in hyaluronidase enzyme activity was measured by the hyaluronidase enzyme activity method in Example 1 (e) and is shown in A (dosage form 9), B (dosage form 10), and C (dosage form 11) in Figure 3. In Table 14 and Figure 3, the content or enzyme activity on Day 0 is set to 100% and the change in activity is shown.
[0140] [Table 14]
[0141] [Table 15]
[0142] As shown in Table 14, the content of each formulation was maintained almost unchanged. As shown in Table 15, basic variants increased during the accelerated stability period, but there was no difference between the formulations. This shows that the effect of each formulation on the antibody is not different between the formulations. As shown in FIG. 3, the hyaluronidase enzyme activity decreased as the content of the surfactant polysorbate 20 increased in formulation 9, while the remaining formulations 10 and 11 did not show a decrease in enzyme activity with an increase in the surfactant content. Formulation 10 containing polysorbate 80 and formulation 11 containing poloxamer 188 showed good maintenance of hyaluronidase enzyme activity despite the increased surfactant content, compared to formulation 9 containing polysorbate 20.
[0143] Example 5. Dosage Form Development: Stability Test of Ocrelizumab Subcutaneous Injection Dosage Form
[0144] As shown in Table 16, subcutaneous injection formulations of ocrelizumab were prepared to confirm the stability of each formulation under harsh conditions. Each formulation contained 30 mg / mL ocrelizumab and was composed of 20 mM sodium acetate (pH 5.5), 106 mM trehalose, 85 mM sodium chloride, and 2000 units / mL hyaluronidase. The hyaluronidases used were HP46 and rHuPH20. 0.04% polysorbate 20 and 0.2% poloxamer 188 were used as surfactants.
[0145] [Table 16]
[0146] The stability of each ocrelizumab subcutaneous injection dosage form listed in Table 16 was confirmed under the harsh conditions of 40±2°C and 60±5% relative humidity. The change in content was measured by the content method using a spectrophotometer in Example 1 (a) and is shown in Table 17. The change in content of the main fraction on size-exclusion chromatography was measured by the size-exclusion chromatography method in Example 1 (b) and is shown in Table 18. The change in hyaluronidase enzyme activity was measured by the hyaluronidase enzyme activity method in Example 1 (e) and is shown in Figure 4. In Tables 17, 18, and Figure 4, the content and enzyme activity on day 0 are set to 100% and the change in activity is shown.
[0147] [Table 17]
[0148] [Table 18]
[0149] As shown in Tables 17 and 18, the content was maintained without significant changes for each formulation. As shown in Figure 4, when poloxamer 188 was used as a surfactant, hyaluronidase enzyme activity was maintained at 60% or more, and when polysorbate 20 was used, enzyme activity was maintained at 40% or more. From this, it is believed that although there is no effect on the antibody by each formulation, the formulation using poloxamer 188 affects the stability of hyaluronidase enzyme activity. There was no significant difference between HP46 and rHuPH20.
[0150] Example 6. Dosage Form Development: Stability Test of Rituximab Subcutaneous Injection Dosage Form
[0151] As shown in Table 19, subcutaneous injection formulations of Rituximab were prepared, and the stability of each formulation under harsh conditions was confirmed. Each formulation contained 120 mg / mL of Rituximab and was basically composed of 20 mM sodium acetate (pH 5.5), 106 mM trehalose, 85 mM sodium chloride, and 2000 units / mL hyaluronidase. The hyaluronidase used was HP46 and rHuPH20. 0.04% polysorbate 20 and 0.2% poloxamer 188 were used as surfactants.
[0152] [Table 19]
[0153] The stability of each rituximab subcutaneous injection dosage form listed in Table 19 was confirmed under the harsh conditions of 40±2°C and 60±5% relative humidity. The change in content was measured by the content method using a spectrophotometer in Example 1 (a) and is shown in Table 20. The change in content of the main fraction on size-exclusion chromatography was measured by the size-exclusion chromatography method in Example 1 (b) and is shown in Table 21. The change in hyaluronidase enzyme activity was measured by the hyaluronidase enzyme activity method in Example 1 (e) and is shown in Figure 5. Tables 20, 21, and Figure 5 show the change in activity, with the content and enzyme activity on day 0 taken as 100%.
[0154] [Table 20]
[0155] [Table 21]
[0156] As shown in Tables 20 and 21, the contents were maintained without significant changes for each formulation. From FIG. 5, it was seen that when poloxamer 188 was used as a surfactant, hyaluronidase enzyme activity was maintained at 20% or more, and when polysorbate 20 was used, it was seen that it decreased to 20% or less. From this, it is considered that each formulation has no effect on the antibody, but the formulation using poloxamer 188 affects the stability of hyaluronidase enzyme activity. There was no significant difference between HP46 and rHuPH20.
[0157] Example 7. Dosage Form Development: Stability Test of Nivolumab Subcutaneous Injection Dosage Form
[0158] Nivolumab subcutaneous injection formulations were manufactured as shown in Table 22, and the stability of each formulation under harsh conditions was confirmed. Each formulation contained 25 mg / mL nivolumab and was basically composed of 20 mM sodium acetate (pH 5.5), 106 mM trehalose, 85 mM sodium chloride, and 2000 units / mL hyaluronidase. HP46 and rHuPH20 were used as hyaluronidase. 0.04% polysorbate 20 and 0.2% poloxamer 188 were used as surfactants.
[0159] [Table 22]
[0160] The stability of each nivolumab subcutaneous injection dosage form listed in Table 22 was confirmed under the harsh conditions of 40±2°C and 60±5% relative humidity. The change in content was measured by the content method using a spectrophotometer in Example 1 (a) and is shown in Table 23. The change in content of the main fraction on size-exclusion chromatography was measured by the size-exclusion chromatography method in Example 1 (b) and is shown in Table 24. The change in hyaluronidase enzyme activity was measured by the hyaluronidase enzyme activity method in Example 1 (e) and is shown in Figure 6. In Table 22, Table 23, and Figure 6, the content and enzyme activity on day 0 are set to 100% and the change in activity is shown.
[0161] [Table 23]
[0162] [Table 24]
[0163] As shown in Tables 23 and 24, the contents were maintained without significant changes for each formulation. From Figure 6, it was seen that when poloxamer 188 was used as a surfactant, the enzyme activity of hyaluronidase HP46 was maintained at 60% or more, and the enzyme activity of hyaluronidase rHuPH20 was maintained at 50% or more, and when polysorbate 20 was used, the enzyme activity of hyaluronidase HP46 was maintained at 50% or more, and the enzyme activity of hyaluronidase rHuPH20 was maintained at 30% or less. From this, it is considered that although there is no effect on the antibody by each formulation, the formulation using HP46 and poloxamer 188 affects the stability of hyaluronidase enzyme activity.
[0164] Example 8. Dosage Form Development: Stability Test of Daratumumab Subcutaneous Injection Dosage Form
[0165] As shown in Table 25, daratumumab subcutaneous injection formulations were prepared and the stability of each formulation under harsh conditions was confirmed. Each formulation contained 60 mg / mL nivolumab and was basically composed of 20 mM sodium acetate (pH 5.5), 106 mM trehalose, 85 mM sodium chloride, and 2000 units / mL hyaluronidase. HP46 and rHuPH20 were used as hyaluronidase. 0.04% polysorbate 20 and 0.2% poloxamer 188 were used as surfactants.
[0166] [Table 25]
[0167] The stability of each daratumumab subcutaneous injection dosage form listed in Table 25 was confirmed under the harsh conditions of 40±2°C and 60±5% relative humidity. The change in content was measured by the content method using a spectrophotometer in Example 1 (a) and is shown in Table 26. The change in content of the main fraction on size-exclusion chromatography was measured by the size-exclusion chromatography method in Example 1 (b) and is shown in Table 27. The change in hyaluronidase enzyme activity was measured by the hyaluronidase enzyme activity method in Example 1 (e) and is shown in Figure 7. Tables 26, 27, and Figure 7 show the change in activity, with the content and enzyme activity on day 0 taken as 100%.
[0168] [Table 26]
[0169] [Table 27]
[0170] As shown in Tables 26 and 27, the contents were maintained without significant changes for each formulation. From Figure 7, it was seen that when poloxamer 188 was used as a surfactant, the enzyme activity of hyaluronidase HP46 was maintained at 80% or more, and the enzyme activity of hyaluronidase rHuPH20 was maintained at 60% or more, and when polysorbate 20 was used, the enzyme activity of hyaluronidase HP46 was maintained at 60% or more, and the enzyme activity of hyaluronidase rHuPH20 was maintained at 50% or less. From this, it is considered that although there is no effect on the antibody by each formulation, the formulation using HP46 and poloxamer 188 affects the stability of hyaluronidase enzyme activity.
[0171] Example 9. Dosage Form Development: Stability Study of Pembrolizumab Subcutaneous Injection Dosage Form
[0172] As shown in Table 28, subcutaneous injection formulations of pembrolizumab were prepared, and the stability of each formulation under harsh conditions was confirmed. Each formulation contained 25 mg / mL pembrolizumab and was composed of 20 mM sodium acetate (pH 5.5), 106 mM trehalose, 85 mM sodium chloride, and 2000 units / mL hyaluronidase. HP46 and rHuPH20 were used as hyaluronidase. 0.2% poloxamer 188 was used as a surfactant.
[0173] [Table 28]
[0174] The stability of each pembrolizumab subcutaneous injection dosage form listed in Table 25 was confirmed under harsh conditions of 40±2°C and 60±5% relative humidity. Changes in hyaluronidase enzyme activity were measured using the hyaluronidase enzyme activity method of Example 1 and are shown in Figure 8. In Figure 8, the content and enzyme activity on each day (day 0) are set to 100% and the changes in activity are shown.
[0175] FIG. 8 shows that when poloxamer 188 was used as a surfactant, the enzyme activity was maintained at 40% or more regardless of the type of hyaluronidase.
[0176] From the above results, when changing the hyaluronidase and surfactant in antibody protein pharmaceuticals, each formulation does not have an effect on the antibody, but the formulation using HP46 and poloxamer 188 is thought to have an effect that enables the maintenance of the stability of hyaluronidase enzyme activity.
[0177] References
[0178] Chen, KJ, Sabrina, S., El-Safory, NS, Lee, GC, and Lee, CK Constitutive expression of recombinant human hyaluronidase PH20 by Pichia pastoris. J Biosci. Bioeng. (2016) 122, 673-678
[0179] Hofinger, ES, Bernhardt, G., and Buschauer, A. Kinetics of Hyal-1 and PH-20 hyaluronidases: comparison of minimal substrates and analysis of the transglycosylation reaction. Glycobiology (2007) 17, 963-971
[0180] Kreidieh, FY, Moukadem, HA, and Saghir, NSE Overview, prevention and management of chemotherapy extravasation. World J. Clin. Oncol. (2016) 7, 87-97.
[0181] Thomas, J.R., Yocum, R.C., Haller, M.F., and Flament J. The INFUSE-Morphine IIB Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneous Morphine in Healthy Volunteers. J. Pain Symptom Manag. (2009) 38, 673-682
[0182] Strickley, R.G., and Lambert, W.J. A review of formulations of commercially available antibodies. J Pharm. Sci. (2021) 110, 2590-2608
[0183] Zarrintaj P., Ramsey J.D., Samadi A., Atoufic Z., Yazdi M.K., Ganjali M.R., Amirabad L.M., Zangene E., Farokhi M., Formela K., Saeb M.R., Mozafari M., and Thomas S. Poloxamer: A versatile tri-block copolymer for biomedical applications. Acta Biomaterialia (2020) 110, 37-67
[0184] Wearable Injectors. OnDrugDelivery (2019) 100, 04-91 [Industrial Applicability]
[0185] The pharmaceutical composition of the present invention is not only usable for subcutaneous injection, but is also very stable, so that the activity of anticancer drugs, preferably antibody drugs, more preferably antibody drugs such as anti-HER2 antibodies and immune checkpoint antibodies, and PH20 mutants can be maintained for a long period of time. Therefore, it can contribute to reducing the production costs of subcutaneous dosage forms as well as medical costs, and is also very advantageous in terms of patient convenience. [Sequence List Free Text]
[0186]
Claims
1. A pharmaceutical composition comprising: (a) a drug; (b) hyaluronidase; and (c) a poloxamer surfactant, The hyaluronidase comprises a wild-type PH20 having the sequence of SEQ ID NO:1 or a PH20 mutant thereof, wherein the PH20 mutant comprises a substitution of one or more amino acid residues selected from the group consisting of T341S, L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, I361T, and N363G in the wild-type PH20 having the sequence of SEQ ID NO:1, and optionally includes an N-terminal and / or C-terminal truncation. A pharmaceutical composition.
2. The pharmaceutical composition of claim 1, wherein the PH20 mutant comprises a substitution of one or more amino acid residues selected from the group consisting of L354I and N356E.
3. The pharmaceutical composition of claim 1, characterized in that the PH20 mutant further comprises a substitution of one or more amino acid residues at one or more sites selected from the group consisting of the alpha helix site and its junction site of the wild-type PH20 of SEQ ID NO:
1.
4. The pharmaceutical composition according to claim 3, characterized in that the alpha helix site of the wild-type PH20 of SEQ ID NO: 1 is the alpha helix 8 site (S347-C381) and the linking site is the linking site between alpha helix 7 and alpha helix 8 (A333-R346).
5. The pharmaceutical composition according to claim 4, wherein the alpha helix portion of the wild-type PH20 of SEQ ID NO: 1 and the portion corresponding to the linking portion are T341 to N363, T341 to I361, L342 to I361, S343 to I361, I344 to I361, M345 to I361, or M345 to N363.
6. The pharmaceutical composition according to claim 4, characterized in that one or more sites selected from the group consisting of the alpha helix 8 site (S347-C381) of the wild-type PH20 of SEQ ID NO: 1 and the junction site between alpha helix 7 and alpha helix 8 (A333-R346) are substituted with a partial amino acid residue of the amino acid sequence of the corresponding site of Hyal1.
7. The PH20 variant comprises a substitution of amino acid residues L354I and / or N356E, The pharmaceutical composition of claim 1, further comprising a substitution of an amino acid residue at one or more positions selected from the group consisting of T341, L342, S343, I344, M345, S347, M348, K349, L352, L353, D355, E359, I361, and N363.
8. The PH20 variant comprises a substitution of amino acid residues L354I and / or N356E, The pharmaceutical composition according to claim 7, further comprising one or more amino acid residue substitutions selected from the group consisting of T341S, L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, D355K, E359D, I361T, and N363G.
9. The pharmaceutical composition of claim 7, wherein the PH20 mutant comprises substitutions of amino acid residues M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T.
10. The pharmaceutical composition of claim 9, wherein the PH20 mutant further comprises one or more amino acid residue substitutions selected from the group consisting of T341S, L342W, S343E, I344N, and N363G.
11. The pharmaceutical composition according to claim 10, characterized in that the PH20 mutant contains any one amino acid substitution selected from the group consisting of: (a) T341S, L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T; (b) L342W, S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T; (c) M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T; (d) M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, I361T, and N363G; (e) I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T; and (f) S343E, I344N, M345T, S347T, M348K, K349E, L352Q, L353A, L354I, D355K, N356E, E359D, and I361T
12. The wild-type PH20 or PH20 mutant is further characterized in that some amino acid residues are deleted at any one or more of the C-terminus and N-terminus. The pharmaceutical composition according to any one of claims 1 to 11.
13. The wild-type PH20 or PH20 mutant is characterized in that some amino acid residues are deleted before an amino acid residue selected from the group consisting of M1 to P42 at the N-terminus. The pharmaceutical composition according to claim 12.
14. The wild-type PH20 or PH20 mutant is characterized in that it is truncated before the N-terminal residues L36, N37, F38, R39, A40, P41, or P42 to delete some amino acid residues. The pharmaceutical composition of claim 13.
15. The wild-type PH20 or PH20 mutant is characterized in that it is truncated next to an amino acid residue selected from the group consisting of V455 to L509 at the C-terminus, resulting in the deletion of some amino acid residues. The pharmaceutical composition according to claim 12.
16. The wild-type PH20 or PH20 mutant is characterized in that it is truncated after an amino acid residue selected from the group consisting of V455 to S490 at the C-terminus, resulting in the deletion of some amino acid residues. The pharmaceutical composition according to claim 15.
17. The wild-type PH20 or PH20 mutant is truncated after the C-terminal residues V455, C458, D461, C464, I465, D466, A467, F468, K470, P471, P472, M473, E474, T475, E476, P478, I480, Y482, A484, P486, T488, or S490 to delete some amino acid residues. The pharmaceutical composition of claim 16.
18. The pharmaceutical composition according to any one of claims 1 to 17, wherein the wild-type PH20 or PH20 mutant further comprises a signal peptide derived from human hyaluronidase-1 (Hyal1), human growth hormone, or human serum albumin at the N-terminus.
19. The pharmaceutical composition according to any one of claims 1 to 17, characterized in that the PH20 mutant is selected from the group consisting of the amino acid sequences of SEQ ID NO: 5 to SEQ ID NO:
50.
20. The pharmaceutical composition of claim 19, wherein the PH20 mutant has the sequence of SEQ ID NO:
44.
21. The pharmaceutical composition according to claim 1, wherein the drug is a protein drug, an antibody, a small molecule compound, an aptamer, an RNAi, an antisense, or a cell therapy agent.
22. The pharmaceutical composition according to claim 21 , wherein the drug is an antibody, a water-soluble receptor, or a fusion protein of a water-soluble receptor and Fc.
23. The antibodies include 4-1BB, 5T4, integrin, activin, amyloid beta, angiopoietin (angiopoietin 1 or 2), angiopoietin analog 3, B cell maturation antigen (BCMA), B cell activating factor (B-cell activating factor), and the like. factor, BAFF), B7-H3, complement 5, CCR4, CCR5, CCL11, CD2, CD3, CD4, C D6, CD11a, CD16A, CD19, CD20, CD22, CD25, CD27, CD28, CD30, CD32B, CD33, CD38, CD40, CD45, CD46, CD47, CD52, CD56, CD62, CD70, CD73, CD74, CD79b, CD80, CD105 , CD123, CD154, CD166, CD262, CD278, CD319, CD326, Carcinoembryonic antigen antigen, CEA), CGRP, Claudin-18, c-Met, CSF-1, CSF-1 receptor, CTLA4, DLL3, EGF receptor, hemophilic factor, Fc receptor, FGF23, folate receptor, GD2, glucocorticoid-induced TNF receptor (GITR), glypican 3, GM-CSF, HER2, HER3, hepatocyte growth factor (Hepatocyte Growth Factor), Factor, HGF), interferon receptor, interferon gamma, IgE, IGF-1 receptor, interleukin 1, interleukin 2 receptor, interleukin 4, interleukin 4 receptor, interleukin 5, interleukin 5 receptor, interleukin 6, interleukin 6 receptor, interleukin 8, interleukin 12 / 23, interleukin 13, interleukin 17A, interleukin 17 receptor A, interleukin 23, interleukin 31 receptor, interleukin 36 receptor, lymphocyte-activation gene 3 (LAG3), lysyl oxidase homolog 2 (Lysyl oxidase homolog 2,LOXL2), mesothelin, mucin-1, mucin-16, netin-4, nerve growth factor (NGF), OX40, proprotein convertase subtilisin / kexin type 9 (PCSK9), PD-1, PD-L1, phospholipase C, RANKL (Receptor activator of nuclear factors kappa B ligand), tyrosine-protein kinase transmembrane receptor (Tyrosine-protein kinase transmembrane receptor (ROR1), sialic acid binding ig-like lectin 15 (Siglec-15), transforming growth factor beta (TGFβ), TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domain), T cell immunoglobulin and mucin-domain containing substance 3 (Tim-3), tissue factor (Tissue factor factor), tissue factor pathway inhibitor (TFPI), TORP-2, tumor necrosis factor (TNF), thymic stromal lymphopoietin (Thymic stromal lymphopoietin) lymphopoietin, TSLB), macrophage stimulating factor 1 receptor (CSF1R), vascular endothelial growth factor factor, VEGF), VEGF receptor, and vWF (von Willebrand The pharmaceutical composition according to claim 22, characterized in that it binds to one or more antigens selected from the group consisting of:
24. The antibodies include ADG 106, EU101, LVGN6051, urelumab, utomilumab, bebtelovimab, aducanumab, bapineuzumab, crenezumab, donanemab, gantenerumab, lecanemab, solanezumab, necanema ... Nesvacumab, Enobritumab, Omburtamab, Belimumab, Ianalumab, Tabalumab, Bertilimumab, Mogamulizumab, Leronlimab, Siplizumab, Foralumab alumab), Muromonab-CD3, Otelixizumab, Teplizumab, Ibalizumab, Tregalizumab, Zanolimumab, Itolizumab, Epalizumab, Inebilizumab, Tafasitamab itamab, Tositumomab, Ocrelizumab, Ofatumumab, Ublituximab, Veltuzumab, Epratuzumab, Basiliximab, Daclizumab, Varlilumab, Lulizumab pegol pegol), Iratumumab, BI-1206, Lintuzumab, Daratumumab, Felzartamab, GEN3014, Isatuximab, Mezagitamab,CDX-1140, Bleselumab, Dacetuzumab, Iscalimab, Lucatumumab, Mitazalimab, SEA-CD40, Sotigalimab, SAR441344, Tegoprovert, Dapirolizumab pegol, I-131 Apamistamab (I-131-Apamistamab), AO-176, Ligufalimab (Ligufalimab), Magrolimab (Magrolimab), Alemtuzumab (Alemtuzumab), Crizanlizumab (Crizanlizumab), Inclacumab (Inclacumab), Cusatuzumab (Cusatuzumab), Oleculumab (Oleculumab), Milatuzumab (Milatuzumab), Galiximab, Carotuximab, Adecatumumab, Eptinezumab, Erenumab, Fremanezumab, Galcanezumab, TST001, ZL-1211, Zolbetuximab, Onartuzumab b), Eculizumab, Pozelimab, Ravulizumab, Lacnotuzumab, PD-0360324, AMB-051, Axatilimab, Cabilalizumab, Emactuzumab, BA3071, Ipilimumab, Cuabonlimab (Quavonlimab), Tremelimumab, Zalifrelimab, Cetuximab, Depatuxizumab, Futuximab, Imgatuzumab, Matuzumab, Modotuximab, Necitumumab,Nimotuzumab, Panitumumab, Tomuzotuximab, Zalutumumab, MK-2060, Batoclimab, Nipocalimab, Rozanolixizumab, Burosumab, Farletuzumab, Dinutuximab, Dinutuximab beta beta), Naxitamab, BMS-986156, Ragifilimab, Gimsilumab, Lenzilumab, Mavrilimumab, Namilumab, Otilima, Polonmarlimab, Codritumab tuzumab), margetuximab, pertuzumab, trastuzumab, HMBD-001, patritumab, seribantumab, durigotuzumab, ficlatuzumab, rilotuzumab, Alomfilimab, Anifrolumab, Emapalumab, FB825, Ligelizumab, Omalizumab, Cixutumumab, Dalotuzumab, Figitumumab, Ganitumab, Teprotumumab, Bermekimab, Canakinumab, Gevokizumab, Briakinumab, Ustekinumab, Anrukinumab, Sendakimab, Lebrikizumab,Tralokinumab, Brodalumab, Bimekizumab, Ixekizumab, Secukinumab, Brazikumab, Guselkumab, Mirikizumab, Risankizumab, Tildrakizumab, Nemolizumab, Imsidolimab, S Pesolimab, Pascolizumab, CBP201, Dupilumab, Depemokinab, Mepolizumab, Reslizumab, Benralizumab, Clazakizumab, Olokizumab, Siltuximab, Sirukumab, Ziltivekimab, Levitra, Levilimab, Sarilumab, Satralizumab, Tocilizumab, HuMax-IL8, Abituzumab, Fabezlimab, Fianlimab, GSK2831781, Ieramilimab, INCAGN02385, Relatlimab, Simtuzumab, Abagovomab, Oregovomab, Oregovomab), Tanezumab, BMS-986178, GSK3174998, INCAGN01949, Ivuxolimab, Rocatinlimab, Tavolimab, Telazorlimab, Vonlerolizumab, Alirocumab, Bococizumab, Ebronucimab, Evolocumab,Frovocimab, Ongericimab, Tafolecimab, Dostarlimab, Balstilimab, Camrelizumab, Cemiplimab, Geptanolimab, MEDI0680, Nivolumab b), Bembrolizumab, Penpulimab, Pidilizumab, Prorugolimab, Retifanlimab, Sasanlimab, Serplulimab, Sintilimab, Spartalizumab ab), tislelizumab, toripalimab, ezabenlimab, zimberelimab, atezolizumab, avelumab, cosibelimab, sugemalimab, durvalumab, IM C-001, Envafolimab, Suvratoxumab, Denosumab, Zilovertamab, NC318, Elotuzumab, NIS793, BMS-986207, Domvanalimab, EOS-448, Etigilimab, Osipellimab (Ociperlimab), Tiragolumab, Vibostolimab, Surzebiclimab, Cobolimab, Sabatolimab, TQB2618, Concizumab, Marstacimab, Adalimumab, Golimumab, Infliximab,Certolimumab pegol, Conatumumab, Tigatuzumab, Tezepelumab, Gatipotuzumab, Cabilalizumab, Bevacizumab, Brolucizumab, lucizumab, ranibizumab, olinvacimab, icrucumab, ramucirumab, caplacizumab, abrilumab, etrolizumab, vedolizumab, intetumumab, natalizumab, DSP107, RO7122290, cinrebafusp alfa, GEN1042, rozibafusp alfaalfa), GEN1044, Obrindatamab, GEN1047, Ellanatamab, Linvoseltamab, Teclistamab, Epcoritamab, Glofitamab, Mosunetuzumab, Odronextamab , Flotetuzumab, Bibecotamab, Catumaxomab, Cibisatamab, TAK-186, Talquetamab, Ubamatamab, NVG-111, Emfizatamab, HPN536, AFM13, Blinatumomab, IS B1442, CPO107, AFM24, Amivatamab, MCLA-129, SI-B001, Emicizumab, Mim8, Zenocutuzumab, Zanidatamab, Tibulizumab, GI-101, Vobarilizumab, REGN5668, HX009, Cadnilimab onilimab), Vudalimab, EMB-02, RO7247669, Tebotelimab, IBI318, AZD2936, AZD7789, RO7121661, Ivonesimab, IBI322, ES101, GEN1046, PRS-344, Erfonrilimab, FS118, Bintrafusp alfa alfa), HB0036, HLX301, NM21-1480, Ozoralizumab, Vanucizumab, Navicixizumab, IBI302, Naptumomab estafenatox, Belantamab mafodotinmafodotin, DS-7300, MGC018, pivekimab sunirine, praluzatamab ravtansine, coltuximab ravtansine, denintuzumab mafodotin, loncastuximab tesirine, ibritumomab tiuxetan, inotuzumab ozogamicin ozogamicin, epratuzumab-cys-tesirine, moxetumomab pasudotox, brentuximab vedotin, gemtuzumab ozogamicin, vadastuximab talirine, STI-6129, FOR46, lorvotuzumab mertansine, polatuzumab vedotin vedotin, Tusamitamab ravtansine, Terisotuzumab vedotin, Rovalpituzumab tesirine, Depatuxizumab mafodotin, Farletuzumab ecteribulin, Mirvetuximab soravtansine, ARX788, Trastuzumab deruxtecan deruxtecan), trastuzumab duocarmazine, A166, trastuzumab emtansine, DP303c, MRG002, BDC-1001, SHR-A1811, dicitamab vedotin, pertuzumab juvotolimodThe pharmaceutical composition according to claim 22, characterized in that the compound is one or more selected from the group consisting of sacituzumab govitecan, sacituzumab govitecan, sacituzumab govitecan, sacituzumab rivtansine ...
25. The pharmaceutical composition according to claim 22, wherein the water-soluble receptor contained in the water-soluble receptor or the fusion protein of the water-soluble receptor and Fc is selected from the group consisting of a TNF-α water-soluble receptor, a VEGF water-soluble receptor, CTLA-4, an interleukin-1 water-soluble receptor, and an LFA3 water-soluble receptor.
26. The fusion protein of the water-soluble receptor and Fc includes Etanercept, Aflibercept, Conbercept, OPT-302, Abatacept, Belatacept, Rilonacept, Inbakicept, Alefacept, 26. The pharmaceutical composition according to claim 25, wherein the active ingredient is selected from the group consisting of acetaminophen, ...
27. A pharmaceutical composition comprising hyaluronidase and a poloxamer-based surfactant.
28. The pharmaceutical composition according to claim 1 or 27, characterized in that the poloxamer surfactant is poloxamer 188.
29. The pharmaceutical composition according to claim 1 or 27, wherein the poloxamer surfactant is contained in an amount of 0.001% to 1.5% (w / v).
30. 30. The pharmaceutical composition according to claim 1 or 27, further comprising one or more selected from the group consisting of a buffer and a stabilizer.
31. The buffering agent may be selected from the group consisting of malate, formate, citrate, acetate, propionate, pyridine, piperazine, cacodylate, succinate, and 2-(N-morpholino)ethanesulfonic acid. acid, MES), histidine, Tris, bis-Tris, phosphate, ethanolamine, carbonate, 2-ethanesulfonic acid (piperazine-N,N'-bis(2-ethanesulfonic acid), PIPES), imidazole, bis-tris propane, BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid one or more buffers selected from the group consisting of hydroxyethyl piperazine ethane sulfonic acid (HEPES), pyrophosphate, and triethanolamine; The pharmaceutical composition according to claim 30, wherein the stabilizer is one or more selected from the group consisting of carbohydrates, sugars or hydrates thereof, sugar alcohols or hydrates thereof, and amino acids.
32. The carbohydrate, sugar or sugar alcohol is at least one selected from the group consisting of trehalose or a hydrate thereof, sucrose, saccharin, glycerol, erythritol, threitol, xylitol, arabitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, polyglycitol, cyclodextrin, hydroxypropyl beta-cyclodextrin, and glucose; The pharmaceutical composition according to claim 31, characterized in that the amino acid is one or more selected from the group consisting of glutamine, glutamic acid, glycine, lysine, cytosine, leucine, methionine, valine, serine, selenomethionine, citrulline, arginine, asparagine, aspartic acid, ornithine, isoleucine, taurine, theanine, threonine, tryptophan, tyrosine, phenylalanine, proline, pyrrolysine, histidine, and alanine.
33. The pharmaceutical composition according to claim 30, comprising 50-350 mg / mL of an antibody, preferably an anti-HER2 antibody or an immune checkpoint antibody, 100-20,000 units / mL of a PH20 variant, 0.001%-1.5% (w / v) of a poloxamer-based surfactant, 0.001-200 mM histidine buffer providing a pH of 5.5±2.0, and 10-400 mM α,α-trehalose, and optionally further comprising 1-50 mM methionine.
34. The pharmaceutical composition according to claim 33, comprising 120±18 mg / mL of an anti-HER2 antibody or immune checkpoint antibody, 1,500-12,000 units / mL of a PH20 variant, 0.1%-0.5% (w / v) of a poloxamer-based surfactant, 10-30 mM histidine buffer providing a pH of 5.5±2.0, 180-230 mM α,α-trehalose, and optionally further comprising 8-15 mM methionine.
35. The pharmaceutical composition according to any one of claims 1 to 34, characterized in that the residual enzyme activity after 7 days is maintained at 40±2°C and is not less than 20%.
36. A dosage form for subcutaneous administration comprising the pharmaceutical composition of any one of claims 1 to 35.
37. 37. The subcutaneous dosage form according to claim 36, which is in a ready-to-injection form without any additional dilution process.
38. The subcutaneous dosage form according to claim 37, which is provided in a pre-filled syringe, a glass ampoule, a plastic container, a wearable device, or an auto-injector.
Citation Information
Patent Citations
Stable formulations of a hyaluronan-degrading enzyme
KR101874401B1
Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
KR1020120105426A
Light emitting device and electronic apparatus comprising same
KR1020220047459A
PH20 polypeptede variants, formulations and uses thereof
WO2013102144A2
Novel hyaluronic acid-hydrolyzing enzyme mutant and pharmaceutical composition comprising same
WO2020022791A1
